A China-made cancer drug is set to go on sale in the US after Americans had been traveling to buy it. The signal is pricing: offshore oncology supply is entering the US market where patients already s

What happened: AstraZeneca said it would start selling a cancer drug in the US after criticism that it had not brought the medicine to the US market faster. Some Americans had travelled to Shanghai to obtain the drug, first developed by China. Why it matters: The criticism and patient travel preceded the company's decision to begin US sales of the China-developed medicine.

China-made cancer drug entering US market signals cross-border demand and regulatory milestone.

China-made cancer drug entering US market signals cross-border demand and regulatory milestone. — impact context not separately stored; see What changed.